Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.50 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.47 |
| ▸ | ACLY | P53396 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27696974 | 0.90 | SERPINE1 (0.46) | HDAC1SERPINE1ACLYHDAC2HDAC3 | |
| SCHEMBL2270475 | 0.88 | HDAC1 (0.43) | HDAC1ACLYHDAC2HDAC3IGF2BP2 | |
| SCHEMBL2273439 | 0.88 | SERPINE1 (0.46) | SERPINE1RAB9ANPC1CYP1A2 | |
| SCHEMBL27716759 | 0.87 | SERPINE1 (0.44) | HDAC1SERPINE1ACLYHDAC2HDAC3 | |
| SCHEMBL2272006 | 0.84 | ACLY (0.62) | HDAC1SERPINE1ACLYHDAC2HDAC3 | |
| SCHEMBL2273488 | 0.83 | SUCNR1 (0.52) | HDAC1SERPINE1ACLYHDAC2HDAC3 | |
| Cyanate SCHEMBL27830146 | 0.83 | HDAC2 (0.51) | HDAC1ACLYHDAC2HDAC3IGF2BP2 | |
| SCHEMBL14428491 | 0.82 | SERPINE1 (0.53) | HDAC1SERPINE1ACLYHDAC2HDAC3 | |
| SCHEMBL2274754 | 0.82 | HDAC2 (0.53) | HDAC1ACLYHDAC2HDAC3IGF2BP2 | |
| SCHEMBL27989086 | 0.82 | HDAC1 (0.56) | HDAC1SERPINE1ACLYHDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | HDAC1 71/4885SERPINE1 101/4885ACLY 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.